Tema Etfs LLC Invests $1.23 Million in Genmab A/S (NASDAQ:GMAB)

Tema Etfs LLC bought a new position in shares of Genmab A/S (NASDAQ:GMAB - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 58,935 shares of the company's stock, valued at approximately $1,230,000.

Other institutional investors have also modified their holdings of the company. Deep Track Capital LP purchased a new position in shares of Genmab A/S during the 4th quarter valued at approximately $41,740,000. Brandywine Global Investment Management LLC acquired a new stake in Genmab A/S in the fourth quarter valued at $33,804,000. Marshall Wace LLP boosted its stake in Genmab A/S by 162.2% during the 4th quarter. Marshall Wace LLP now owns 1,122,296 shares of the company's stock valued at $23,422,000 after acquiring an additional 694,243 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in Genmab A/S during the 4th quarter worth $12,360,000. Finally, Russell Investments Group Ltd. grew its holdings in Genmab A/S by 18,959.1% during the 4th quarter. Russell Investments Group Ltd. now owns 510,784 shares of the company's stock worth $10,660,000 after acquiring an additional 508,104 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company's stock.

Genmab A/S Stock Down 1.8%

GMAB traded down $0.37 during trading on Friday, reaching $20.66. The stock had a trading volume of 479,685 shares, compared to its average volume of 1,123,566. The stock has a 50 day moving average of $19.76 and a two-hundred day moving average of $20.71. The firm has a market capitalization of $13.25 billion, a price-to-earnings ratio of 11.87, a price-to-earnings-growth ratio of 2.65 and a beta of 1.04. Genmab A/S has a 1-year low of $17.24 and a 1-year high of $29.96.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.08. The business had revenue of $715.00 million during the quarter, compared to analyst estimates of $5.17 billion. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. On average, research analysts forecast that Genmab A/S will post 1.45 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently commented on GMAB. Sanford C. Bernstein cut shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a research report on Tuesday, April 1st. Leerink Partners raised Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 target price on the stock in a report on Thursday, February 13th. Truist Financial lowered their price target on Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a report on Tuesday, March 11th. BNP Paribas upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 11th. Finally, Leerink Partnrs raised shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $39.17.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.